AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7486767 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stay group (drains removed and discharged after 48 h)
Number of subjects: 100
Study 7486767 — intervention group
Group type: COMPARATOR
Intervention: Long stay group (discharged when drainage was considered acceptable, mean postoperative stay 4.5 days)
Number of subjects: 100
Study 1730312 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamete intrafallopian transfer (GIFT)
Number of subjects: 174
Study 1730312 — intervention group
Group type: COMPARATOR
Intervention: Conventional infertility treatment (induction of ovulation with gonadotropins followed by intrauterine artificial insemination or normal intercourse)
Number of subjects: 174
Study 6712850 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg
Number of subjects: 40
Study 6712850 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 40
Study 31008635 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive cognitive therapy (PCT), 8 weekly sessions
Number of subjects: 214
Study 31008635 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 214
Study 29421065 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% topical capsaicin
Number of subjects: 10
Study 29421065 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study 27103232 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored program (access to all modules)
Number of subjects: 0
Study 27103232 — intervention group
Group type: COMPARATOR
Intervention: Control group (access to FAQs, project information and counseling checklist only)
Number of subjects: 0
Study 27103232 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored program
Number of subjects: 0
Study 22936334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training
Number of subjects: 60
Study 22936334 — intervention group
Group type: COMPARATOR
Intervention: Land training (control)
Number of subjects: 60
Study 22936334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Aquatic and Land)
Number of subjects: 60
Study 21679214 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide (40mg t.d.s. for 15 weeks)
Number of subjects: 356
Study 20351868 — intervention group
Group type: COMPARATOR
Intervention: Web-only self-care education (access to a website and email access to a cardiac nurse)
Number of subjects: 0
Study 20351868 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based sessions with a cardiac nurse (access to the website and four telephone sessions)
Number of subjects: 0
Study 16404229 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysmal SAH
Number of subjects: 99
Study 16404229 — intervention group
Group type: EXPERIMENTAL
Intervention: PNSAH
Number of subjects: 99
Study 16404229 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 99
Study 15656211 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (leuprolide acetate, 3.75 mg, intramuscular injections every 28 days for 3 months)
Number of subjects: 41
Study 15656211 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg orally, 2 times per day for 3 months)
Number of subjects: 41
Study 15656211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative treatment, underwent ovarian stimulation immediately after first menses within 3 months postoperatively)
Number of subjects: 41
Study 11712342 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 15
Study 11712342 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 15
Study 9192396 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician lifestyle modification (10 structured visits of 15-20 minutes)
Number of subjects: 26
Study 9192396 — intervention group
Group type: COMPARATOR
Intervention: Group behavior modification (32 sessions of 75 minutes)
Number of subjects: 26
Study 9192396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (physician and group behavior modification)
Number of subjects: 26
Study 9192396 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in the first four weeks and daily food records completion
Number of subjects: 26
Study 1556279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural factors influencing adult attitudes
Number of subjects: 382
Study 1556279 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of education
Number of subjects: 382
Study 3925335 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 622
Study 3925335 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 622
Study 3925335 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 622
Study 3925335 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 622
Study 3925335 — intervention group
Group type: COMPARATOR
Intervention: Control of tonic-clonic seizures
Number of subjects: 622
Study 31337170 — intervention group
Group type: EXPERIMENTAL
Intervention: TFESI with sedation
Number of subjects: 64
Study 31337170 — intervention group
Group type: COMPARATOR
Intervention: TFESI without sedation
Number of subjects: 64
Study 28944524 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous positive airway pressure (n = 34)
Number of subjects: 65
Study 28944524 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure (n = 31)
Number of subjects: 65
Study 28944524 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous positive airway pressure (after 24 weeks)
Number of subjects: 65
Study 28944524 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous positive airway pressure (after 24 weeks, compliant patients)
Number of subjects: 65
Study 27406705 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA sheet attached to surgical wounds
Number of subjects: 17
Study 27406705 — intervention group
Group type: COMPARATOR
Intervention: Nonattached side (control)
Number of subjects: 17
Study 25164315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 100
Study 25164315 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 100
Study 25164315 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 100
Study 23146280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with paclitaxel (E-T-CMF)
Number of subjects: 308
Study 23146280 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant treatment with epirubicin followed by CMF (E-CMF)
Number of subjects: 308
Study 20703222 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg intravenous dose of rifampin
Number of subjects: 10
Study 20703222 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg dose of warfarin alone
Number of subjects: 10
Study 18829803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group using the American Academy of Pediatrics curriculum
Number of subjects: 1212
Study 18829803 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1212
Study 18829803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1212
Study 15677288 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-skills program (S.S.GRIN)
Number of subjects: 381
Study 15677288 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 381
Study 11818761 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the lateralization control point (10-mA current, 299 Hz on dominant side, 149 Hz on contralateral side)
Number of subjects: 20
Study 11818761 — intervention group
Group type: COMPARATOR
Intervention: Control (no electrical stimulation)
Number of subjects: 20
Study 10406365 — intervention group
Group type: EXPERIMENTAL
Intervention: Better pain treatment
Number of subjects: 0
Study 10406365 — intervention group
Group type: COMPARATOR
Intervention: Standard pain control
Number of subjects: 0
Study 2135070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol 600 mg
Number of subjects: 12
Study 2135070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol 1200 mg
Number of subjects: 12
Study 2135070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 378623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-dopa 1000 mg
Number of subjects: 0
Study 378623 — intervention group
Group type: COMPARATOR
Intervention: L-dopa placebo
Number of subjects: 0
Study 378623 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 0
Study 31155223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention website (I-DECIDE)
Number of subjects: 422
Study 31155223 — intervention group
Group type: COMPARATOR
Intervention: Control website (static intimate partner violence information website)
Number of subjects: 422
Study 27091596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Alendronate (ALN) gel
Number of subjects: 90
Study 27091596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Atorvastatin (ATV) gel
Number of subjects: 90
Study 27091596 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study 24820545 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition-lag training
Number of subjects: 31
Study 24820545 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 31
Study 22996024 — intervention group
Group type: EXPERIMENTAL
Intervention: AET/RET 1 × wk
Number of subjects: 63
Study 22996024 — intervention group
Group type: EXPERIMENTAL
Intervention: AET/RET 2 × wk
Number of subjects: 63
Study 22996024 — intervention group
Group type: EXPERIMENTAL
Intervention: AET/RET 3 × wk
Number of subjects: 63
Study 22996024 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study 21343762 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor epidural analgesia
Number of subjects: 200
Study 19712124 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized assessment and treatment program (IATP)
Number of subjects: 110
Study 19712124 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive packaged CBT program (PCBT)
Number of subjects: 110
Study 17387131 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin combined with 60 mg of torcetrapib for 2 years
Number of subjects: 850
Study 17387131 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 850
Study 15492573 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL/kg intraoperative administration of lactated Ringer's solution (LR)
Number of subjects: 48
Study 15492573 — intervention group
Group type: COMPARATOR
Intervention: 15 mL/kg intraoperative administration of lactated Ringer's solution (LR)
Number of subjects: 48
Study 11446476 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 2,500 IU once daily
Number of subjects: 102
Study 11446476 — intervention group
Group type: COMPARATOR
Intervention: Standard Heparin 5,000 IU three times daily
Number of subjects: 102
Study 9572995 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 400 microg/m2 IV over 30 minutes once daily
Number of subjects: 234
Study 9572995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 9572995 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 234
Study 8071389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 4 days)
Number of subjects: 21
Study 8071389 — intervention group
Group type: COMPARATOR
Intervention: Temazepam (10 mg single oral dose)
Number of subjects: 21
Study 3342282 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of benzydamine hydrochloride with ICEBERG AR 84/05/15 flavoring agent
Number of subjects: 0
Study 3342282 — intervention group
Group type: COMPARATOR
Intervention: Liquid formulation of benzydamine hydrochloride without ICEBERG AR 84/05/15 flavoring agent
Number of subjects: 0
Study 31882376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, with dose increase to 150 mg every 2 weeks at week 12 if week 8 LDL-C was >1.81 mmol/L)
Number of subjects: 615
Study 31882376 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 615
Study 31882376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 615
Study 31882376 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 615
Study 29266308 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg once daily
Number of subjects: 84
Study 29266308 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 100 mg once daily
Number of subjects: 84
Study 29266308 — intervention group
Group type: COMPARATOR
Intervention: PF-06700841 (various doses)
Number of subjects: 84
Study 29266308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 28394215 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame program (30 minutes per week for 2 weeks)
Number of subjects: 337
Study 28394215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exergame intervention)
Number of subjects: 337
Study 25119580 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment with warning about side effects
Number of subjects: 91
Study 25119580 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment without warning about side effects
Number of subjects: 91
Study 25119580 — intervention group
Group type: COMPARATOR
Intervention: No treatment with warning about side effects
Number of subjects: 91
Study 25119580 — intervention group
Group type: COMPARATOR
Intervention: No treatment without warning about side effects
Number of subjects: 91
Study 23672267 — intervention group
Group type: EXPERIMENTAL
Intervention: rhANP 0.1 μg/kg/min
Number of subjects: 48
Study 23672267 — intervention group
Group type: EXPERIMENTAL
Intervention: rhANP 0.2 μg/kg/min
Number of subjects: 48
Study 23672267 — intervention group
Group type: EXPERIMENTAL
Intervention: rhANP 0.05 μg/kg/min
Number of subjects: 48
Study 23672267 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 48
Study 20439384 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based nurse-directed smokeless tobacco cessation intervention including peer-led educational sessions and oral exams by the school nurse with brief tobacco cessation counseling.
Number of subjects: 4731
Study 20439384 — intervention group
Group type: COMPARATOR
Intervention: No-intervention group (control).
Number of subjects: 4731
Study 20439384 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline nonsmoking ST users.
Number of subjects: 4731
Study 18520292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab at 15 mg/kg every 3 weeks
Number of subjects: 0
Study 18520292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab at 7.5 or 15 mg/kg every 3 weeks
Number of subjects: 0
Study 18520292 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel
Number of subjects: 0
Study 18520292 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine
Number of subjects: 0
Study 16176312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainstem method
Number of subjects: 60
Study 16176312 — intervention group
Group type: COMPARATOR
Intervention: Marker method
Number of subjects: 60
Study 16176312 — intervention group
Group type: COMPARATOR
Intervention: Formula method
Number of subjects: 60
Study 16176312 — intervention group
Group type: COMPARATOR
Intervention: Marker method (age-stratified 3-12 months)
Number of subjects: 60
Study 12687554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) continued for >300 days
Number of subjects: 90
Study 12687554 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (ALN) discontinued (<90 days of therapy)
Number of subjects: 90
Study 10400478 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg twice daily)
Number of subjects: 386
Study 10400478 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) (84 microg four times daily)
Number of subjects: 386
Study 10400478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 10400478 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 386
Study 10400478 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 386
Study 8911782 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified micronized flavonoid fraction (Daflon 500 mg)
Number of subjects: 40
Study 8911782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1868678 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin (750 mg every 12 hours for five doses)
Number of subjects: 13
Study 1868678 — intervention group
Group type: EXPERIMENTAL
Intervention: temafloxacin (600 mg every 12 hours for five doses)
Number of subjects: 13
Study 1868678 — intervention group
Group type: COMPARATOR
Intervention: placebo (given every 12 hours for five doses)
Number of subjects: 13
Study 6109798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Na diet supplemented with potassium for 2 weeks (low Na/high K)
Number of subjects: 0
Study 6109798 — intervention group
Group type: EXPERIMENTAL
Intervention: High Na diet
Number of subjects: 0
Study 6109798 — intervention group
Group type: COMPARATOR
Intervention: Low Na diet
Number of subjects: 0
Study 6109798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Na diet supplemented with potassium (low Na/high K)
Number of subjects: 0
Study 30326264 — intervention group
Group type: COMPARATOR
Intervention: Vicagrel 5 mg
Number of subjects: 79
Study 30326264 — intervention group
Group type: COMPARATOR
Intervention: Vicagrel 20 mg
Number of subjects: 79
Study 30326264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicagrel 25 mg
Number of subjects: 79
Study 29116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity levels
Number of subjects: 0
Study 29116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer symptoms of depression
Number of subjects: 0
Study 29116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Less stress and/or anxiety (decreased mood)
Number of subjects: 0
Study 29116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Less back pain
Number of subjects: 0
Study 29116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger social support
Number of subjects: 0
Study 29116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of low work demands
Number of subjects: 0
Study 25888657 — intervention group
Group type: EXPERIMENTAL
Intervention: Faded feedback group (HRV biofeedback with reduced feedback over sessions)
Number of subjects: 20
Study 25888657 — intervention group
Group type: COMPARATOR
Intervention: Full feedback group (continuous HRV biofeedback)
Number of subjects: 20
Study 23962220 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Number of subjects: 700
Study 23962220 — intervention group
Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 700
Study 20609136 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE for food items
Number of subjects: 85
Study 20609136 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE for beef
Number of subjects: 85
Study 19497707 — intervention group
Group type: EXPERIMENTAL
Intervention: DCD-training group (table-tennis training program, 10 weeks, 3 times a week)
Number of subjects: 27
Study 19497707 — intervention group
Group type: COMPARATOR
Intervention: DCD non-training group
Number of subjects: 27
Study 16715780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 0
Study 16715780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15612841 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP delivered by university clinicians (U-PREP)
Number of subjects: 217
Study 15612841 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP delivered by RO clergy (RO-PREP)
Number of subjects: 217
Study 15612841 — intervention group
Group type: COMPARATOR
Intervention: Naturally occurring (NO) marriage preparation
Number of subjects: 217
Study 11352439 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 500mg (Calcium‐Sandoz Forte) administered before, and 12 and 24 hours after moxifloxacin
Number of subjects: 12
Study 11352439 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400mg without calcium
Number of subjects: 12
Study 9164427 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone 30 mg daily
Number of subjects: 30
Study 9164427 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 8220803 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms once daily
Number of subjects: 83
Study 8220803 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms once daily
Number of subjects: 83
Study 8220803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 3121343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipofundin MCT (10%)
Number of subjects: 6
Study 3121343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (10%)
Number of subjects: 6
Study 3121343 — intervention group
Group type: COMPARATOR
Intervention: Lipofundin S (10%)
Number of subjects: 6
Study 30285715 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition A: Only one audience member present
Number of subjects: 49
Study 30285715 — intervention group
Group type: COMPARATOR
Intervention: Condition B: Presence of an audience of 5 health care providers
Number of subjects: 49
Study 26285691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg daily
Number of subjects: 19
Study 26285691 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate 100 mg daily
Number of subjects: 19
Study 25002002 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-independent population management IT application involving PCPs
Number of subjects: 103870
Study 25002002 — intervention group
Group type: COMPARATOR
Intervention: Automated reminder system
Number of subjects: 103870
Study 22911615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DRZ)
Number of subjects: 255
Study 22911615 — intervention group
Group type: COMPARATOR
Intervention: No dexrazoxane
Number of subjects: 255